Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P24821
UPID:
TENA_HUMAN
Alternative names:
Cytotactin; GMEM; GP 150-225; Glioma-associated-extracellular matrix antigen; Hexabrachion; JI; Myotendinous antigen; Neuronectin; Tenascin-C
Alternative UPACC:
P24821; C9IYT7; C9J575; C9J6D9; C9J848; Q14583; Q15567; Q5T7S3
Background:
Tenascin-C, also known as Cytotactin or Neuronectin, is a pivotal extracellular matrix protein that plays a crucial role in the development of the nervous system. It is involved in guiding neuron migration, axon development, synaptic plasticity, and neuronal regeneration. Tenascin-C acts as a ligand for several integrins, facilitating cell adhesion processes critical for tissue development and repair.
Therapeutic significance:
The protein's association with autosomal dominant deafness, DFNA56, highlights its clinical relevance. This condition, characterized by progressive sensorineural hearing loss, underscores the importance of Tenascin-C in auditory system function. Understanding the role of Tenascin-C could open doors to potential therapeutic strategies for hearing impairment and other neurodevelopmental disorders.